Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis

References

• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099-109
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006;166:2381-7
   PubMed Web of Science ®Google Scholar
• Lemack GE. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Nat Clin Pract Urol 2007;4:174-5
   PubMedGoogle Scholar
• Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228-43
   PubMed Web of Science ®Google Scholar
• Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009;56:810-20
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011;60:94-105
   PubMed Web of Science ®Google Scholar
• Filson CP, Hollingsworth JM, Clemens JQ, et al. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol 2013;190:2153-60
   PubMed Web of Science ®Google Scholar
• Hao N, Tian Y, Liu W, et al. Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms – a meta-analysis. Urology 2014;83:556-62
   PubMed Web of Science ®Google Scholar
• Wang X, Wang X, Li S, et al. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One 2014;9:e107593
   PubMed Web of Science ®Google Scholar
• Li MC, Wang ZY, Yang J, et al. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Asian J Androl 2015;17:124-34
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Kjaergard LL, Villumsen J, Gluud C. Quality of randomized clinical trials affects estimates of intervention efficacy. In: Cochrane Colloquium. Dissertation, 7th edn. Rome: Univ S Tommaso Daquino, 1999
   Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998;352:609-13
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms – ASSIST, randomized controlled study. Urology 2011;78:126-33
   PubMed Web of Science ®Google Scholar
• Lee SH, Byun SS, Lee SJ, et al. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol 2014;46:523-9
   PubMed Web of Science ®Google Scholar
• Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013;64:1003-12
   PubMed Web of Science ®Google Scholar
• Liang Y, Xu F, Gao JP, et al. Tamsulosin combined with solifenacin improved the intractable LUTS caused by BPH patients significantly. J Med Res 2012;41:77-9
   Google Scholar
• Follmann D, Elliott P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epid 1992;45:769-73
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Kaplan SA, He W, Koltun WD, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013;63:158-65
   PubMed Web of Science ®Google Scholar
• Shin YS, Zhang LT, Zhao C, et al. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. Clin Interv Aging 2014;9:1021-30
   PubMedGoogle Scholar
• Ko K, Yang DY, Lee WK, et al. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. Korean J Urol 2014;55:608-14
   PubMedGoogle Scholar
• Shalaby E, Ahmed AF, Maarouf A, et al. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent-related lower urinary symptoms. Adv Urol 2013;2013:752382
   PubMedGoogle Scholar
• Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol 2013;64:398-407
   PubMed Web of Science ®Google Scholar
• Seo DH, Kam SC, Hyun JS. Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function. Korean J Urol 2011;52:49-54
   PubMedGoogle Scholar
• Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol 2013;189:S129-34
   Google Scholar
• Bauer HW, Casarosa C, Cosci M, et al. Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschr Med 1999;41:127-32
   Google Scholar
• Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J 2011;5(5 Suppl 2):S143-5
   Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803
   PubMed Web of Science ®Google Scholar
• Russo A, La Croce G, Capogrosso P, et al. Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opin Pharmacother 2014;15:2319-28
   PubMed Web of Science ®Google Scholar
• Cho KJ, Kang SH, Kim HS, et al. Effect of 5-alpha reductase inhibitor on storage symptoms in patients with benign prostatic hyperplasia. Int Neurourol J 2011;15:152-7
   PubMedGoogle Scholar
• Montorsi F, Roehrborn C, Garcia-Penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int 2011;107:1426-31
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
   PubMed Web of Science ®Google Scholar
• Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999;288:1367-73
   PubMed Web of Science ®Google Scholar
• Michel MC, Ochodnicky P, Homma Y, et al. beta-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 2011;131:40-9
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar
• Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A. Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication? Neurourol Urodyn 2010;29(Suppl 1):S46-50
   Google Scholar
• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol 2015;67:262-70
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
   PubMed Web of Science ®Google Scholar
• Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 2010;29:97-106
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88
   PubMedGoogle Scholar